Dr. Stone Discusses Monitoring MRD in AML

(1:34)

The role of MRD in AML regulatory decision making

(3:27)

Dr. Konopleva on the Controversies Surrounding MRD in AML

(4:53)

MRD in myeloma: the FDA perspective

(1:26)

Current role of MRD in AML

(1:12)

Developments for the use of MRD in AML

(1:17)

The emerging role of MRD in colorectal cancer decision making

(2:53)

Top 1 M82B/AWM malaysia without scope

(1:40:6)

The current role of MRD in AML and challenges with implementing this in clinical practice

(1:26)

The importance of MRD in AML prognosis and therapy

(2:16)

Approaches to and the use of MRD in ALL

(5:17)

Methods to evaluate MRD in AML

(1:32)

The role of MRD in AML

(4:22)

MRD in AML clinical practice

(2:5)

MRD in AML: ELN recommendations

(2:45)

MRD in pediatric ALL: clinical evidence, treatment decisions \u0026 outcomes

(2:4)

Measuring MRD in AML: current landscape and future outlook

(1:6)

The evolving role of MRD in DLBCL

(2:30)